Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This Phase 1 study assesses the safety, pharmacokinetics, and preliminary activity of Cevostamab in participants with relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Cevostamab (cevostamab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING